Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBIRTH: Bromocriptine for Peripartum Cardiomyopathy
NCT05180773Phase 4Recruiting
- Start
- Jul 2022
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bromocriptine in Peripartum cardiomyopathy (PPCM) (3 arms). Primary endpoint: Left ventricular ejection fraction at 6 months. Started Jul 2022; status: recruiting.
02
Drugs
bromocriptine
03
Conditions
Peripartum cardiomyopathy (PPCM)
Beyond the preview
Go deeper on NCT05180773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180773.